18:50 , Jan 12, 2018 |  BC Week In Review  |  Clinical News

Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

Innovation Pharmaceuticals Inc. (OTCQB:IPIX) reported top-line data from 46 patients receiving chemoradiation for head and neck cancer in the modified intent-to-treat (mITT) population of a Phase II trial showing that thrice-daily 45 mg/15 mL Brilacidin-OM...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Brilacidin-OM: Phase II started

Cellceutix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate Brilacidin-OM oral rinse thrice daily for up to 7 weeks in 60 patients with head and neck cancer undergoing chemoradiation. Cellceutix Corp. (OTCQB:CTIX), Beverly,...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Brilacidin-OM: Phase II start

Next month, Cellceutix will begin a double-blind, placebo-controlled, U.S. Phase II trial of once-daily Brilacidin-OM for 7 days in patients with head and neck cancer receiving chemotherapy and radiotherapy. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass.  ...